Alumis Halts Undisclosed Drug Development, Tepezza Rivalry Ends Alumis Inc. halted its undisclosed drug program. Phase 3 development will not proceed. This removes a Tepezza competitor. Amgen's market position strengthens. Alumis Inc. has ceased development of its undisclosed drug, a potential rival to Amgen's Tepezza (teprotumumab) for Thyroid Eye Disease (TED). The company confirmed it will not advance the program to a planned Phase 3 trial. This decision follows an internal assessment of the drug's prospects, though specific trial phase or endpoint metrics triggering the halt were not disclosed. The move signals a strategic shift for Alumis. This halt means Alumis will not seek further regulatory approvals from agencies like the FDA or EMA for this specific indication. For a drug to reach market, successful Phase 3 data is typically required for a New Drug Application (NDA) or Marketing Authorization Application (MAA). Without Phase 3, the drug cannot progress through the regulatory pathway outlined in 21 CFR Part 312 for investigational new drugs. Alumis will now explore strategic alternatives for the program. The cessation benefits Amgen, solidifying Tepezza's dominance in the TED market. This removes a key potential competitor, reducing future market share erosion. Horizon Therapeutics, acquired by Amgen, developed Tepezza. Other competitors in the TED space include Viridian Therapeutics. Amgen's next earnings call, expected in late July 2026, may reflect this reduced competitive pressure.